Fas ligand expression in nodal non-Hodgkin's lymphoma.
Fas (Apo-1/CD95) ligand (FasL) is a cytotoxic molecule used by T lymphocytes and natural killer cells for target-cell killing and by nonmalignant and malignant cells in the suppression of immune responses. In this study, FasL expression in B- and T-cell non-Hodgkin's lymphomas was investigated by paraffin immunohistochemical analysis. FasL expression was found to be weak in nonaggressive lymphomas (chronic lymphocytic leukemia/small lymphocytic lymphoma, lymphoplasmacytoid lymphoma, Grade 1 follicular center cell lymphoma) and mantle cell lymphoma but strong in aggressive B-cell lymphomas (diffuse large B-cell lymphoma, Burkitt's-lymphoma). Precursor B-lymphoblastic lymphomas were more heterogeneous, with expression varying from weak to strong. In T-cell lymphomas (anaplastic large-cell lymphoma; peripheral T-cell lymphoma, unspecified), strong FasL expression was observed. Apparently, FasL expression is not limited to neoplasms derived from T cells or natural killer cells, and it might play a supporting role in the progression of non-Hodgkin's lymphomas.
Müllauer
L
L
Institute of Clinical Pathology, University of Vienna, AKH-General Hospital, Austria. leonhard.muellauer@akh-wien.ac.at
Mosberger
I
I
Chott
A
A
D001402:B-Lymphocytes / Q000737:chemistry / Q000473:pathology; D053222:Fas Ligand Protein; D006801:Humans; D007150:Immunohistochemistry; D019169:Jurkat Cells / Q000737:chemistry; D008198:Lymph Nodes / Q000737:chemistry; D016393:Lymphoma, B-Cell / Q000737:chemistry / Q000473:pathology; D017728:Lymphoma, Large-Cell, Anaplastic / Q000737:chemistry; D008228:Lymphoma, Non-Hodgkin / Q000737:chemistry* / Q000473:pathology; D016399:Lymphoma, T-Cell / Q000737:chemistry / Q000473:pathology; D016411:Lymphoma, T-Cell, Peripheral / Q000737:chemistry; D008562:Membrane Glycoproteins / Q000096:biosynthesis* / Q000378:metabolism; D014407:Tumor Cells, Cultured / Q000737:chemistry
C505661:FASLG protein, human; D053222:Fas Ligand Protein; D008562:Membrane Glycoproteins